key: cord-0912137-9edyn6on authors: Salari, Abolfazl; Jalaeefar, Amirmohsen; Shirkhoda, Mohammad title: What is the best treatment option for head and neck cancers in COVID-19 pandemic? A rapid review date: 2020-09-18 journal: Am J Otolaryngol DOI: 10.1016/j.amjoto.2020.102738 sha: f25e1ed40d8b2932a895de074fc1ef093743fb79 doc_id: 912137 cord_uid: 9edyn6on With the onset of the COVID-19 crisis in late 2019, the health care systems of different countries are experiencing stressful conditions. Many patients need care in hospital wards and intensive care units (ICU). Head & neck cancers (HNC) are in a special condition in this pandemic. The main treatment in these patients is surgery. Most of these patients need care in the ICU, which is reduced in capacity in pandemic conditions. It's important to note that delays in the surgery of these patients make them non-operable and on the other hand increase mortality and morbidity. Numerous non-surgical alternative therapies have been proposed in these conditions, but there are fundamental questions about these suggestions. 1 How long should we look for alternative therapies? Because many countries are facing a second wave of the disease. 2 What's the effect of these alternative therapies and the delay in starting standard treatments in patients' survival? Different countries have different financial resources; many countries, patients face restrictions on receiving alternative therapies to standard treatments, and in non-pandemic conditions, long queues are given for non-surgical treatments such as chemo-radiotherapy. There are numerous guidelines to guide head and neck surgeons to the best choice in this situation. It seems that different countries have to make individual decisions based on the prevalence of COVID-19 and the financial resources and facilities of the health care system. In this review article, we have collected the opinions of world-renowned guidelines and institutions on how to treat HNCs during the pandemic. In December 2019 some pneumonia cases with an unknown source were reported in Wuhan, China. The causative micro-organism, a novel coronavirus, was named 2019-nCOV or COVID-19 by world health organization (WHO)(1, 2). In January 2020 WHO announced the virus a Public Health Emergency of International Concern (PHEIC) (2) . The involvement of all countries around the world, more than 27 million people infected, and around 900,000 victims until September 8, show that the world is facing a disastrous pandemic. (3) The novel coronavirus is highly contagious and its transmission can occur via droplets or contact with nasal or oral mucosal surfaces. It has been also proposed that another way of virus dissemination could be aerosol, although to prove this needs more investigations (4, 5) . The mean incubation period of the disease is 5.5 days and 14 days of isolation after the beginning of symptoms are sufficient for transmission control (6) . Fever, cough, dyspnea, and fatigue are the most common symptoms of the disease, however, about 18 percent of the patients are asymptomatic and can play a role in virus transmission (7, 8) . The mortality rate of the infection is reported to be around 2.3% but can be significantly higher in patients above 70 years old. The mortality rate among patients suffering from cancer is 5.6% though it was anticipated to be higher due to their immunosuppression (9) . The need for intensive care unit (ICU) admission and intubation was also reported higher in cancer patients compared to COVID-19 patients. (10) Deciding on the best treatment modality for head and neck cancer (HNC) patients is particularly complicated in the current situation due to the limited surgical and non-surgical resources. It necessitates utilizing multidisciplinary team (MDT) meetings to opt for the best treatment plan for any individual patient. (11) The possibility of infection with COVID-19 for patient and health care workers, the patient's comorbidities, the prognosis of the intervention, the effect of the treatment modality on quality of life, and the rate of acute complications are factors to be considered while choosing the best option of treatment. (12) Surgery is the main treatment for HNC patients. The surgeries are almost always prolonged, requiring ICU admission, mechanical ventilation, and the involvement of many health care workers both in J o u r n a l P r e -p r o o f the operation and in the pre-operative care. The use of ICU beds and ventilators for COVID -19 patents' care & the engagement of the medical staff in their treatment cause a delay in the treatment of HNC patients which may lead tumor progression, increase in the surgical resection field, complication, recurrences, and mortality (13) . Moreover, performing safe surgical operations faces many challenges in the current situation. The limitations in COVID-19 patients' screening, the possibility of transmission during the incubation period and by asymptomatic patients, the shortage of personal protective equipment (PPE), and the high viral load in upper aero-digestive tract (UADT) are some of these challenges (14) . Also, when the surgical procedure is done under general anesthesia, intubation and bag-valve mask ventilation may increase the chance of infection as aerosol-generating procedures (AGP). Tracheotomy, airway suctioning, and endotracheal tube substitution are other instances of AGP related to HNC surgeries (14) . Head & neck surgeons, too face a high risk of COVID-19 infection due to their surgical procedures on UADT which have a high viral load of COVID-19. (15) Because of the above reasons and the unknown future of COVID-19 disease at present, we should change some of our previous treatment strategies of HNC and consider new strategies that may not necessarily follow the standard guidelines. Different countries of the world have different financial resources and this variation leads in turn to different strategy planning for the distribution of resources between the treatment of COVID-19 and other diseases. Moreover, HNC patients are diagnosed at different stages in different countries, which affects the decisions on their treatment. Since the beginning of the pandemic, several guidelines and recommendations for HNC management have been published by authoritative scientific centers around the world. Given that in many developing countries proposed alternative therapies such as chemoradiotherapy instead of radical surgery it is not affordable due to the limited accessibility of radiotherapy centers and their long waiting lists, therefore it isn't practical to use a single guideline in different conditions of the countries. As the second wave of the pandemic is expected these days, the present paper aims to review different opinions and studies on the subject which may be of help to different centers of the world to make the best decision in treating their patients based on their conditions & resources. J o u r n a l P r e -p r o o f The physicians of the University of Texas Southern Medical Center believe that in cases of primary mucosal SCC where the results of both surgical and nonsurgical treatment are the same, definitive nonsurgical modalities are preferable in the current pandemic situation. But the daily attendance of patients in radiotherapy centers and the immunosuppression that follows chemotherapy threaten the patients. It seems that in cases such as T1aN0 glottic or T1N0 tonsil SCC surgery is preferable to 7 weeks of undergoing radiotherapy. (14) The University of Texas Southwestern Medical Center's physicians believe the case is different with tumors for which surgery is the main treatment; These include oral cavity cancers (OCC), T4a laryngeal, advanced sinonasal and recurrent UADT cancers. The cost-benefit comparison is simple in low-risk patients (i.e. patients who have passed their 14 days of quarantine, have been asymptomatic during this period, and COVID-19 test negative 48 hours before the surgery) with OCC or sinonasal cancer whose postoperative hospital stay is short. But in the case of advanced sinonasal and advanced laryngeal tumors, most of OCC and patients who require salvage surgeries a longer hospital stay and /or tracheostomy, laryngectomy, and/or free flap are required and the COVID-19 infection risk therefore increases. In such cases, alternative treatments seem to be more reasonable. We can use neoadjuvant chemotherapy (NAC)± cetuximab or NAC ± Immunotherapy to buy time for the health care system until the stabilization of the current situation when standard treatments can be provided. Induction chemotherapy could also be used to surmount the patients' symptoms and have the appropriate delay until the optimal surgical treatment. (14) Surgeons at the University of Pittsburgh, USA give the highest priority to mucosal SCC surgeries in the current situation.(16) When tracheostomy placement is not required, the French Society of Otorhinolaryngology, Head & Neck Surgery (SFORL) recommends surgical treatment for UADT SCC patients who will face poor prognosis if their treatment is delayed beyond one month. When tracheostomy is necessary, however, the recommendation is either to delay the surgery or to choose an alternative modality. (17, 18) The study of the Stanford University Division of Head & Neck surgery; the mucosal SCC patients are ascribed the highest J o u r n a l P r e -p r o o f priority for surgery and is recommended to undergo surgical intervention without any delay. In the case of the limitation of resources, HPV negative patients are prioritized to positive ones. (19) Mehanna et al published the opinions of 40 HNC experts from 35 scientific societies in a setting of severe resource limitation in the Lancet Oncology journal. More than 95% of these experts believe that a delay of above 8 weeks is unacceptable in the surgical treatment of early T1-T2 N0 oral cancers. In cases where surgery is anticipated within 4-8 weeks or after 8 weeks since diagnosis, 87.5% and 67.5% of the physicians (respectively) believe that the patient should undergo recurrent examinations and intervention should take place only in case of any tumor progression. 82.5% are against rapid initiation of non-surgical treatments such as radiotherapy in cases where surgery is anticipated within 4-8 weeks. 92.5% believe that surgery should not be delayed beyond 8 weeks in cases of early T1-N0 laryngeal cancer. 70% believe that radiotherapy could be initiated immediately as an alternative for surgery. In cases where a delay of 4-8 weeks is anticipated, 67.5% believe that radiotherapy should replace surgery, while a majority of 92.5% recommend radiotherapy in cases where more than 8 weeks of delay is anticipated. In advanced HNC cases where prolonged operation or admission is required (such as T4N1 cancer of the larynx, N2b OCC or cases where bone resection is mandatory) a strong agreement exists between more than 87.5% of experts that surgery should not be delayed beyond 4 weeks and if surgery is not feasible within this time, 90% recommend alternative treatments such as radiotherapy or chemo-radiotherapy. There is disagreement on using induction chemotherapy for these cases as long as the surgery is possible, and only 50% of The advice of NCCN is that WLE should be postponed for 3 months in T1& in situ melanoma. Surgery is preferable in T3/T4 rather than T1/T2 cases. Also, sentinel lymph node biopsy (SLNB) should be delayed for 3 months unless WLE is planned in which case SLNB should be done concurrently. In patients with palpable cervical lymphadenopathy, lymph node dissection is not recommended in the current situation and neoadjuvant treatments should be crisis. (22) The first recommendation is not to delay radiotherapy for more than 4 to 6 weeks; radical radiotherapy for HNSCC and adjuvant Radiotherapy for HNSCC with Involved margin has a high priority for treatment. But adjuvant radiotherapy is a lower priority for HNSCC with minor risk factors. During the early stages of the pandemic when the resources needed for radiotherapy are available (Scenario 1), it is recommended that radiotherapy be performed following the same protocol as before. However, during the later stages pandemic and when there is a severe decrease of available resources for radiotherapy (Scenario 2), there is a strong recommendation to perform hypo-fractionated radiotherapy (fewer sessions and higher doses per session). (22) Reducing the number of surgeries will deprive a large number of patients of surgical treatment and radiotherapy will be chosen as an alternative treatment for them. The increase in the number of patients in radiotherapy centers and the decrease of the number of staff (due to the viral infection) result in considering hypo-fractionated radiotherapy as an J o u r n a l P r e -p r o o f alternative method during this particular situation to provide treatment for more patients and reduce the patients' referrals. (36) Also, Cisplatin at a dose of 80-100 mg/m2 every 3 weeks or 30-40 mg/m2 per week is the standard treatment for concomitant chemotherapy (CCT); In early pandemic conditions, CCT is more appropriate, but in late pandemic conditions, CCT will be removed. The members of these associations also recommend performing (chemo-) radiotherapy in OCSCC patients when surgery is not possible due to the closure of operating rooms. (22) The physicians of the University of Texas Southwestern Medical Center recommend replacing standard surgical treatment with primary radiation ± chemotherapy for limited and selected cases of OCSCC, T4a laryngeal SCC and advanced sinonasal malignancy; However, patients should be aware of the lower effectiveness of these treatments compared to standard treatments. Also, in cases that require salvage surgery and have been disease-free for a long time, Re-irradiation ± chemotherapy is an appropriate alternative to surgery. (14) Chemotherapy should not be used in patients over 70 years of age due to its failure to improve survival, and neither in people under 70 with comorbidities due to the high risk of death from COVID-19. Induction chemotherapy with a cisplatin-based regimen is also not recommended. (37) The national health service (NHS) of England also categorized patients who need chemotherapy according to six priorities; Patients who have at least 50% chance of successful treatment by curative chemotherapy, and patients whose chance of successful treatment would be increased at least 50% by adjuvant chemotherapy or NAC along with surgery or radiotherapy have the highest priority for chemotherapy in the crisis. The lower the chance of successful treatment with chemotherapy is, the less would be the priority of the treatment. The priority also decreases in cases of palliative treatment. In radiotherapy treatment, the NHS has ascribed the highest priority to patients who have a high-growth mass and are currently undergoing curative radical (chemo) radiotherapy, or those who are currently undergoing external beam radiotherapy or have a brachytherapy plan following external beam radiotherapy. Radical radiotherapy in less aggressive cancers where radiotherapy is definitive J o u r n a l P r e -p r o o f treatment or adjuvant radiotherapy in rapid proliferating cancers that have residue after surgery are the next priorities. Adjuvant radiotherapy in complete resection patients and also in cases of palliative radiotherapy has the lowest priority. (38) A study in China was conducted concerning 34 asymptomatic patients who underwent elective surgeries and began having symptoms after the surgery. The RT-PCR test was performed it was determined that all patients had COVID-19 and had been in the incubation stage at the time of surgery. 44% of these patients were transferred to the ICU and 20.5% died. Old age, prolonged surgery, and underlying diseases such as cardiovascular disease, cancer, and hypertension led to poorer outcomes for the patients. (39) It is therefore recommended to perform RT-PCR before surgery. Some centers even consider it necessary to have a second negative test before any surgery. (16) If the testing supplies are limited, a chest CT scan (that seems to be more accurate in diagnosing patients with COVID-19) can be used as well. (40) Considering the different pandemic situation in different countries and the limited diagnostic resources, it seems that patients who have UADT surgery, old age, or comorbidities should be prioritized for testing. If the patient tests positive for COVID-19, the surgery must be delayed unless the delay threatens the patient's life. The patient can be tested again 7 days after the disappearance of symptoms or 14 days after the last test, whichever is longer. (19) ESTRO and ASTRO suggest that radiotherapy treatment be delayed in patients with COVID-19 infection if treatment has not been initiated. In patients with mild symptoms who were infected during treatment, it is recommended to continue the treatment especially if they have completed 2 weeks of treatment. But in patients with Sever COVID-19, the treatment must be discontinued and delayed. (22) Conclusion: In deciding on the treatment plan we should take into consideration the importance of timely treatment of patients with HNC especially mucosal UADT SCC, the high probability of COVID-19 transmission especially in asymptomatic patients during surgery on UADT, and the difference in rates of COVID-19 infection and resource such as PPE, ICU, and operating rooms in different areas. It is recommended that centers examine each patient individually by MDT and determine the costs and benefits of delay in the standard treatment or alternative treatment. The risk of infection with the virus and its possible resulted complications for the patient should also be taken into account in the choice of treatment. Considering the reducing resources for cancer patients' surgery and the shift of large numbers of patients to alternative therapies, the limited therapeutic capacity of these treatments, and the postponement of diagnostic and follow-up measures even after the COVID-19 crisis, the challenges in the management of patients with cancer will continue to exist due to the overloading of health care because of the delayed treatments. Therefore, it will be necessary to share the experiences of different countries and medical centers to handle the situation. Understanding of COVID-19 based on current evidence Rolling updates on coronavirus disease (COVID-19 Droplets and Aerosols in the Transmission of SARS-CoV-2 Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1 The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application Epidemiology and Clinical Features of COVID-19: A Review of Current Literature COVID-19 transmission through asymptomatic carriers is a challenge to containment. Influenza and Other Respiratory Viruses Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China COVID-19 pandemic & head and neck cancer patients management: The role of virtual multidisciplinary team meetings Evidence-Based Guidelines for Management of Head and Neck Mucosal Malignancies during the COVID-19 Pandemic Increased pathologic upstaging with rising time to treatment initiation for head and neck cancer: a mechanism for increased mortality Head and neck oncology during the COVID-19 pandemic: Reconsidering traditional treatment paradigms in light of new surgical and other multilevel risks Impact of coronavirus (COVID-19) on otolaryngologic surgery: brief commentary Major head and neck reconstruction during the COVID-19 pandemic: The University of Pittsburgh approach French consensus on management of head and neck cancer surgery during COVID-19 pandemic COVID-19 and ENT surgery Framework for prioritizing head and neck surgery during the COVID-19 pandemic Recommendations for head and neck surgical oncology practice in a setting of acute severe resource constraint during the COVID-19 pandemic: an international consensus. The Lancet Oncology Changes in head and neck oncologic practice during the COVID-19 pandemic Practice recommendations for risk-adapted head and neck cancer radiotherapy during the COVID-19 pandemic: an ASTRO-ESTRO consensus statement Head and neck surgical oncology in the time of a pandemic: Subsite-specific triage guidelines during the COVID-19 pandemic Mitigation of head and neck cancer service disruption during COVID-19 in Hong Kong through telehealth and multi-institutional collaboration Surgical management of head and neck tumours during the SARS-CoV (Covid-19) pandemic British Association of Head & Neck Oncologists. BAHNO Statement on Covid-19 BAHNO laryngectomy guidance during COVID-19 pandemic Failure of free flaps in head and neck oncology surgery in COVID-19 patients. Plastic and reconstructive surgery American Association of Endocrine Surgeons. Thoughts on elective endocrine surgery from AAES members Endocrine Surgery during the Covid-19 pandemic British Association of Endocrine & Thyroid Surgeons. BAETS Prioritisation advice for Adult Endocrine Surgery during Covid-19 crisis Endocrine surgery in the Coronavirus disease 2019 pandemic: Surgical Triage Guidelines Adapting Head and Neck Cancer Management in the Time of COVID-19 The impact of Coronavirus (COVID-19) on head and neck cancer patients' care Clinical guide for the management of non-coronavirus patients requiring acute treatment: Cancer Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases The authors declare that they have no competing interests related to this study. No financial support was received for this study.